- Home
- YOSH vs DARE Comparison
YOSH vs DARE Comparison
Compare YOSH & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- DARE
- Stock Information
- Founded
- YOSH 2016
- DARE 2015
- Country
- YOSH United States
- DARE United States
- Employees
- YOSH N/A
- DARE N/A
- Industry
- YOSH Restaurants
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- DARE Health Care
- Exchange
- YOSH Nasdaq
- DARE Nasdaq
- Market Cap
- YOSH 23.7M
- DARE 28.0M
- IPO Year
- YOSH 2022
- DARE N/A
- Fundamental
- Price
- YOSH $1.71
- DARE $2.13
- Analyst Decision
- YOSH
- DARE Strong Buy
- Analyst Count
- YOSH 0
- DARE 2
- Target Price
- YOSH N/A
- DARE $10.00
- AVG Volume (30 Days)
- YOSH 204.9K
- DARE 167.6K
- Earning Date
- YOSH 08-20-2025
- DARE 08-14-2025
- Dividend Yield
- YOSH N/A
- DARE N/A
- EPS Growth
- YOSH N/A
- DARE N/A
- EPS
- YOSH N/A
- DARE N/A
- Revenue
- YOSH $13,902,861.00
- DARE N/A
- Revenue This Year
- YOSH N/A
- DARE $74,787.57
- Revenue Next Year
- YOSH N/A
- DARE $141.76
- P/E Ratio
- YOSH N/A
- DARE N/A
- Revenue Growth
- YOSH 30.39
- DARE N/A
- 52 Week Low
- YOSH $0.68
- DARE $1.83
- 52 Week High
- YOSH $5.63
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- YOSH 39.12
- DARE 47.26
- Support Level
- YOSH $1.22
- DARE $2.00
- Resistance Level
- YOSH $1.95
- DARE $2.19
- Average True Range (ATR)
- YOSH 0.16
- DARE 0.09
- MACD
- YOSH 0.01
- DARE 0.03
- Stochastic Oscillator
- YOSH 13.70
- DARE 56.52
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.